Predictive biomarker validation in practice: lessons from real trials
نویسندگان
چکیده
منابع مشابه
Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection
The anticipated biological and clinical utility of biomarkers has attracted significant interest recently. Aging and early cancer detection represent areas active in the search for predictive and prognostic biomarkers. While applications differ, overlapping biological features, analytical technologies and specific biomarker analytes bear comparison. Mitochondrial DNA (mtDNA) as a biomarker in b...
متن کاملLessons from practice
The incidence of EM is unclear, but it is thought to affect less than 1% of the population, with a slight predominance among young women.1 EM is characterised by targetoid lesions distributed in peripheral acral regions, and macular, papular and urticarial patterns peripherally and on the extensor surfaces, and, less frequently, diffusely on the trunk. Oral and genital lesions are generally pre...
متن کاملLessons from practice
The hallmark of diabetic ketoacidosis (DKA) is the triad of hyperglycaemia, ketonaemia and metabolic acidosis. The pathogenesis of DKA involves a relative insulin deficiency and an excess of counterregulatory hormones.1 Interplay between these factors results in reduced glucose utilisation and increased gluconeogenesis, together with increased lipolysis and ketogenesis. DKA is classically assoc...
متن کاملBiomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.
The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory stud...
متن کاملLessons from clinical trials in systemic sclerosis
The pathogenesis of systemic sclerosis (SSc) is complex and largely unclear. The clinical heterogeneity of the disease and its progression over a number of years makes the choice of endpoints in the design of clinical trials difficult. The overwhelming need in this disease is to diagnose it early and identify those patients who will benefit most from early, aggressive treatment that potentially...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Trials
سال: 2010
ISSN: 1740-7745,1740-7753
DOI: 10.1177/1740774510368574